Supernus Pharmaceuticals annual free cash flow per share
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2022
2023
2024
2025
Supernus Pharmaceuticals Free Cash Flow Per Share Growth & History (SUPN)
Supernus Pharmaceuticals's free cash flow per share was $0.81 for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.81 | -$2.29 | −73.78% |
| 2024 | 2024-12-31 | $3.11 | $1.08 | +53.32% |
| 2023 | 2023-12-31 | $2.03 | -$0.14 | −6.57% |
| 2022 | 2022-12-31 | $2.17 | — | — |
| 2020 | 2020-12-31 | $2.56 | -$0.11 | −4.25% |
| 2019 | 2019-12-31 | $2.68 | $0.21 | +8.68% |
| 2018 | 2018-12-31 | $2.46 | $0.25 | +11.09% |
| 2017 | 2017-12-31 | $2.22 | $0.90 | +68.32% |
| 2016 | 2016-12-31 | $1.32 | $0.64 | +93.06% |
| 2015 | 2015-12-31 | $0.68 | $1.28 | — |
| 2014 | 2014-12-31 | -$0.59 | $1.28 | — |
| 2013 | 2013-12-31 | -$1.87 | $0.88 | — |
| 2012 | 2012-12-31 | -$2.75 | $20.22 | — |
| 2011 | 2011-12-31 | -$22.97 | -$2.29 | — |
| 2010 | 2010-12-31 | -$20.68 | — | — |
Supernus Pharmaceuticals quarterly free cash flow per share
Q1.11
Q2.11
Q3.11
Q1.12
Q2.12
Q3.12
Q1.13
Q2.13
Q3.13
Q1.14
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.09 | -$1.13 | — |
| Q1 2026 | 2026-03-31 | $1.15 | $0.61 | +112.96% |
| Q4 2025 | 2025-12-31 | $0.34 | — | — |
| Q3 2025 | 2025-09-30 | -$1.09 | -$2.06 | — |
| Q2 2025 | 2025-06-30 | $1.04 | $0.39 | +60.28% |
| Q1 2025 | 2025-03-31 | $0.54 | -$0.15 | −22.17% |
| Q3 2024 | 2024-09-30 | $0.97 | $0.31 | +47.79% |
| Q2 2024 | 2024-06-30 | $0.65 | $1.00 | — |
| Q1 2024 | 2024-03-31 | $0.70 | -$0.20 | −22.49% |
| Q3 2023 | 2023-09-30 | $0.65 | $0.40 | +156.97% |
| Q2 2023 | 2023-06-30 | -$0.35 | -$1.67 | — |
| Q1 2023 | 2023-03-31 | $0.90 | $0.83 | +1288.14% |
| Q3 2022 | 2022-09-30 | $0.25 | — | — |
| Q2 2022 | 2022-06-30 | $1.32 | $0.45 | +51.25% |
| Q1 2022 | 2022-03-31 | $0.06 | -$0.59 | −90.13% |
| Q2 2021 | 2021-06-30 | $0.87 | -$0.87 | −49.81% |
| Q1 2021 | 2021-03-31 | $0.66 | $0.53 | +439.81% |
| Q3 2020 | 2020-09-30 | $0.10 | -$0.61 | −85.44% |
| Q2 2020 | 2020-06-30 | $1.74 | $1.19 | +217.89% |
| Q1 2020 | 2020-03-31 | $0.12 | -$0.50 | −80.61% |
| Q3 2019 | 2019-09-30 | $0.71 | -$0.48 | −40.51% |
| Q2 2019 | 2019-06-30 | $0.55 | $0.43 | +354.39% |
| Q1 2019 | 2019-03-31 | $0.63 | $0.10 | +20.06% |
| Q3 2018 | 2018-09-30 | $1.19 | $0.44 | +57.71% |
| Q2 2018 | 2018-06-30 | $0.12 | -$0.38 | −76.03% |
| Q1 2018 | 2018-03-31 | $0.52 | $0.26 | +100.35% |
| Q3 2017 | 2017-09-30 | $0.76 | $0.19 | +34.44% |
| Q2 2017 | 2017-06-30 | $0.50 | $0.18 | +53.75% |
| Q1 2017 | 2017-03-31 | $0.26 | $0.33 | — |
| Q3 2016 | 2016-09-30 | $0.56 | $0.58 | — |
| Q2 2016 | 2016-06-30 | $0.33 | $0.03 | +11.20% |
| Q1 2016 | 2016-03-31 | -$0.07 | -$0.08 | — |
| Q3 2015 | 2015-09-30 | -$0.02 | $0.09 | — |
| Q2 2015 | 2015-06-30 | $0.29 | $0.46 | — |
| Q1 2015 | 2015-03-31 | $0.01 | $0.48 | — |
| Q3 2014 | 2014-09-30 | -$0.11 | $0.40 | — |
| Q2 2014 | 2014-06-30 | -$0.17 | $0.36 | — |
| Q1 2014 | 2014-03-31 | -$0.47 | $0.10 | — |
| Q3 2013 | 2013-09-30 | -$0.51 | -$0.04 | — |
| Q2 2013 | 2013-06-30 | -$0.53 | $0.05 | — |
| Q1 2013 | 2013-03-31 | -$0.57 | $5.46 | — |
| Q3 2012 | 2012-09-30 | -$0.48 | $5.27 | — |
| Q2 2012 | 2012-06-30 | -$0.58 | $5.21 | — |
| Q1 2012 | 2012-03-31 | -$6.03 | $0.25 | — |
| Q3 2011 | 2011-09-30 | -$5.75 | — | — |
| Q2 2011 | 2011-06-30 | -$5.79 | — | — |
| Q1 2011 | 2011-03-31 | -$6.28 | — | — |
Supernus Pharmaceuticals free cash flow per share trends
Over the last five fiscal years, Supernus Pharmaceuticals's free cash flow per share decreased from $2.56 to $0.81, a change of -$1.75. The latest reported quarter, Q2 2026, shows -$0.09.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
